| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2A |
| Uniprot No | P49459 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MSTPARRRLM RDFKRLQEDP PAGVSGAPSE NNIMVWNAVI FGPEGTPFED GTFKLTIEFT EEYPNKPPTV RFVSKMFHPN VYADGSICLD ILQNRWSPTY DVSSILTSIQ SLLDEPNPNS PANSQAAQLY QENKREYEKR VSAIVEQSWR DC |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2A重组蛋白的3篇参考文献及摘要概述：
---
1. **文献名称**：*UBE2A interacts with the prion protein and participates in its quality control*
**作者**：Díaz-Hernández, M., et al.
**摘要**：该研究探讨了UBE2A与朊蛋白(PrP)的相互作用，发现UBE2A通过泛素-蛋白酶体系统调控PrP的稳定性。作者利用重组UBE2A蛋白进行体外泛素化实验，揭示了UBE2A在错误折叠PrP降解中的关键作用。
---
2. **文献名称**：*Functional characterization of UBE2A mutations in X-linked intellectual disability*
**作者**：Nelson, J.K., et al.
**摘要**：研究分析了UBE2A基因突变与X连锁智力障碍的关联。通过重组UBE2A蛋白的酶活性测定和结构模拟，发现突变导致其泛素结合能力下降，影响突触蛋白稳态及神经元功能。
---
3. **文献名称**：*Recombinant expression and purification of human UBE2A for structural studies*
**作者**：Chen, Z., et al.
**摘要**：报道了一种高效的大肠杆菌表达系统，用于生产高纯度重组UBE2A蛋白。通过X射线晶体学分析其三维结构，为研究UBE2A的底物识别机制及药物靶点开发提供了基础。
---
注：以上文献信息为示例性内容，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of UBE2A Recombinant Protein**
UBE2A (Ubiquitin-Conjugating Enzyme E2 A), also known as RAD6A, is a member of the E2 ubiquitin-conjugating enzyme family that plays a critical role in the ubiquitin-proteasome system (UPS). This system regulates protein degradation, DNA repair, and various cellular processes by tagging target proteins with ubiquitin molecules, marking them for proteasomal destruction. UBE2A specifically catalyzes the transfer of ubiquitin from E1 ligases to substrate proteins, often in coordination with E3 ubiquitin ligases, ensuring substrate specificity.
Recombinant UBE2A protein is engineered through molecular cloning and expression in heterologous systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional form of the enzyme. This allows researchers to study its biochemical properties, enzymatic activity, and interactions with E3 ligases or substrates in controlled settings. UBE2A is notable for its involvement in transcriptional regulation, DNA damage repair, and cell cycle control. Mutations in the *UBE2A* gene are linked to X-linked intellectual disability (XLID) and other neurodevelopmental disorders, highlighting its importance in neuronal function.
Studies using recombinant UBE2A have advanced understanding of its role in diseases such as cancer, where dysregulated ubiquitination contributes to tumor progression. Additionally, it serves as a tool for screening potential therapeutic compounds targeting the UPS. The recombinant form retains post-translational modification capacity when expressed in eukaryotic systems, making it valuable for structural studies and drug development. Its application spans basic research on protein turnover mechanisms to translational studies exploring UPS-related pathologies.
×
